Cardiomyopathy due to PRDM16 mutation: First description of a fetal presentation, with possible modifier genes.


Journal

American journal of medical genetics. Part C, Seminars in medical genetics
ISSN: 1552-4876
Titre abrégé: Am J Med Genet C Semin Med Genet
Pays: United States
ID NLM: 101235745

Informations de publication

Date de publication:
03 2020
Historique:
received: 25 11 2019
accepted: 09 01 2020
pubmed: 23 1 2020
medline: 7 1 2021
entrez: 23 1 2020
Statut: ppublish

Résumé

PRDM16 (positive regulatory domain 16) is localized in the critical region for cardiomyopathy in patients with deletions of chromosome 1p36, as defined by Gajecka et al., American Journal of Medical Genetics, 2010, 152A, 3074-3083, and encodes a zinc finger transcription factor. We present the first fetal case of left ventricular non-compaction (LVNC) with a PRDM16 variant. The third-trimester obstetric ultrasound revealed a hydropic fetus with hydramnios and expanded hypokinetic heart. After termination of pregnancy, foetopathology showed a eutrophic fetus with isolated cardiomegaly. Endocardial fibroelastosis was associated with non-compaction of the myocardium of the left ventricle. Exome sequencing (ES) identified a de novo unreported p.(Gln353*) heterozygous nonsense variant in PRDM16. ES also identified two rare variants of unknown significance, according to the American College of Medical Genetics and Genomics guidelines, in the titin gene (TTN): a de novo missense p.(Lys14773Asn) variant and a c.33043+5A>G variant inherited from the mother. Along with the PRDM16 de novo probably pathogenic variant, TTN VOUS variants could possibly contribute to the severity and early onset of the cardiac phenotype. Because of the genetic heterogeneity of cardiomyopathies, large panels or even ES could be considered as the main approaches for the molecular diagnosis, particularly in fetal presentations, where multiple hits seem to be common.

Identifiants

pubmed: 31965688
doi: 10.1002/ajmg.c.31766
doi:

Substances chimiques

DNA-Binding Proteins 0
PRDM16 protein, human 0
Transcription Factors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

129-135

Subventions

Organisme : Conseil régional de Bourgogne-Franche-Comté
ID : plan d'actions régional pour l'innovation (PARI)
Pays : International
Organisme : European Union
ID : PO FEDER-FSE Bourgogne 2014/2020 programs
Pays : International

Informations de copyright

© 2020 Wiley Periodicals, Inc.

Références

Akinrinade, O., Heliö, T., Lekanne Deprez, R. H., Jongbloed, J. D. H., Boven, L. G., van den Berg, M. P., … Koskenvuo, J. (2019). Relevance of titin missense and non-frameshifting insertions/deletions variants in dilated cardiomyopathy. Scientific Reports, 9(1), 4093. https://doi.org/10.1038/s41598-019-39911-x
Amendola, L. M., Jarvik, G. P., Leo, M. C., McLaughlin, H. M., Akkari, Y., Amaral, M. D., … Rehm, H. L. (2016). Performance of ACMG-AMP variant-interpretation guidelines among nine laboratories in the Clinical Sequencing Exploratory Research Consortium. American Journal of Human Genetics, 98(6), 1067-1076. https://doi.org/10.1016/j.ajhg.2016.03.024
Arndt, A.-K., Schafer, S., Drenckhahn, J.-D., Sabeh, M. K., Plovie, E. R., Caliebe, A., … Klaassen, S. (2013). Fine mapping of the 1p36 deletion syndrome identifies mutation of PRDM16 as a cause of cardiomyopathy. American Journal of Human Genetics, 93(1), 67-77. https://doi.org/10.1016/j.ajhg.2013.05.015
Battaglia, A., Hoyme, H. E., Dallapiccola, B., Zackai, E., Hudgins, L., McDonald-McGinn, D., … Carey, J. C. (2008). Further delineation of deletion 1p36 syndrome in 60 patients: A recognizable phenotype and common cause of developmental delay and mental retardation. Pediatrics, 121(2), 404-410. https://doi.org/10.1542/peds.2007-0929
Bjork, B. C., Turbe-Doan, A., Prysak, M., Herron, B. J., & Beier, D. R. (2010). Prdm16 is required for normal palatogenesis in mice. Human Molecular Genetics, 19(5), 774-789. https://doi.org/10.1093/hmg/ddp543
Dong, X., Fan, P., Tian, T., Yang, Y., Xiao, Y., Yang, K., … Zhou, X. (2017). Recent advancements in the molecular genetics of left ventricular noncompaction cardiomyopathy. Clinica Chimica Acta; International Journal of Clinical Chemistry, 465, 40-44. https://doi.org/10.1016/j.cca.2016.12.013
Duhoux, F. P., Ameye, G., Montano-Almendras, C. P., Bahloula, K., Mozziconacci, M. J., Laibe, S., … Belgian Cytogenetic Group for Haematology and Oncology (BCG-HO). (2012). PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies. British Journal of Haematology, 156(1), 76-88. https://doi.org/10.1111/j.1365-2141.2011.08918.x
Elliott, P., Andersson, B., Arbustini, E., Bilinska, Z., Cecchi, F., Charron, P., … Keren, A. (2008). Classification of the cardiomyopathies: A position statement from the European Society of Cardiology Working Group on myocardial and pericardial diseases. European Heart Journal, 29(2), 270-276. https://doi.org/10.1093/eurheartj/ehm342
Gajecka, M., Saitta, S. C., Gentles, A. J., Campbell, L., Ciprero, K., Geiger, E., … Shaffer, L. G. (2010). Recurrent interstitial 1p36 deletions: Evidence for germline mosaicism and complex rearrangement breakpoints. American Journal of Medical Genetics: Part A, 152A(12), 3074-3083. https://doi.org/10.1002/ajmg.a.33733
Haas, J., Frese, K. S., Peil, B., Kloos, W., Keller, A., Nietsch, R., … Meder, B. (2015). Atlas of the clinical genetics of human dilated cardiomyopathy. European Heart Journal, 36(18), 1123-1135a. https://doi.org/10.1093/eurheartj/ehu301
Hastings, R., de Villiers, C. P., Hooper, C., Ormondroyd, L., Pagnamenta, A., Lise, S., … Gehmlich, K. (2016). Combination of whole genome sequencing, linkage, and functional studies implicates a missense mutation in titin as a cause of autosomal dominant cardiomyopathy with features of left ventricular noncompaction. Circulation: Cardiovascular Genetics, 9(5), 426-435. https://doi.org/10.1161/CIRCGENETICS.116.001431
Herman, D. S., Lam, L., Taylor, M. R. G., Wang, L., Teekakirikul, P., Christodoulou, D., … Seidman, C. E. (2012). Truncations of titin causing dilated cardiomyopathy. The New England Journal of Medicine, 366(7), 619-628. https://doi.org/10.1056/NEJMoa1110186
Jarvik, G. P., & Browning, B. L. (2016). Consideration of cosegregation in the pathogenicity classification of genomic variants. American Journal of Human Genetics, 98(6), 1077-1081. https://doi.org/10.1016/j.ajhg.2016.04.003
Jordan, V. K., Zaveri, H. P., & Scott, D. A. (2015). 1p36 deletion syndrome: An update. The Application of Clinical Genetics, 8, 189-200. https://doi.org/10.2147/TACG.S65698
Leman, R., Gaildrat, P., Gac, G. L., Ka, C., Fichou, Y., Audrezet, M.-P., … Houdayer, C. (2018). Novel diagnostic tool for prediction of variant spliceogenicity derived from a set of 395 combined in silico/in vitro studies: An international collaborative effort. Nucleic Acids Research, 46(15), 7913-7923. https://doi.org/10.1093/nar/gky372
Levitas, A., Konstantino, Y., Muhammad, E., Afawi, Z., Marc Weinstein, J., Amit, G., … Parvari, R. (2016). D117N in cypher/ZASP may not be a causative mutation for dilated cardiomyopathy and ventricular arrhythmias. European Journal of Human Genetics, 24(5), 666-671. https://doi.org/10.1038/ejhg.2015.195
Li, S., Zhang, C., Liu, N., Bai, H., Hou, C., Song, L., & Pu, J. (2019). Titin-truncating variants are associated with heart failure events in patients with left ventricular non-compaction cardiomyopathy. Clinical Cardiology, 42(5), 530-535. https://doi.org/10.1002/clc.23172
Li, S., Zhang, C., Liu, N., Bai, H., Hou, C., Wang, J., … Pu, J. (2018). Genotype-positive status is associated with poor prognoses in patients with left ventricular noncompaction cardiomyopathy. Journal of the American Heart Association, 7(20), e009910. https://doi.org/10.1161/JAHA.118.009910
Long, P. A., Evans, J. M., & Olson, T. M. (2017). Diagnostic yield of whole exome sequencing in pediatric dilated cardiomyopathy. Journal of Cardiovascular Development and Disease, 4(3), 11. https://doi.org/10.3390/jcdd4030011
Maron, B. J., Towbin, J. A., Thiene, G., Antzelevitch, C., Corrado, D., Arnett, D., … Council on Epidemiology and Prevention. (2006). Contemporary definitions and classification of the cardiomyopathies: An American Heart Association scientific statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation, 113(14), 1807-1816. https://doi.org/10.1161/CIRCULATIONAHA.106.174287
Nambot, S., Thevenon, J., Kuentz, P., Duffourd, Y., Tisserant, E., Bruel, A.-L., … Orphanomix Physicians' Group. (2018). Clinical whole-exome sequencing for the diagnosis of rare disorders with congenital anomalies and/or intellectual disability: Substantial interest of prospective annual reanalysis. Genetics in Medicine, 20(6), 645-654. https://doi.org/10.1038/gim.2017.162
Nguyen, K., Roche, S., Donal, E., Odent, S., Eicher, J.-C., Faivre, L., … Habib, G. (2019). Whole exome sequencing reveals a large genetic heterogeneity and revisits the causes of hypertrophic cardiomyopathy. Circulation: Genomic and Precision Medicine, 12(5), e002500. https://doi.org/10.1161/CIRCGEN.119.002500
Pugh, T. J., Kelly, M. A., Gowrisankar, S., Hynes, E., Seidman, M. A., Baxter, S. M., … Funke, B. H. (2014). The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing. Genetics in Medicine, 16(8), 601-608. https://doi.org/10.1038/gim.2013.204
Richard, P., Ader, F., Roux, M., Donal, E., Eicher, J., Aoutil, N., … Charron, P. (2019). Targeted panel sequencing in adult patients with left ventricular non-compaction reveals a large genetic heterogeneity. Clinical Genetics, 95(3), 356-367. https://doi.org/10.1111/cge.13484
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., … ACMG Laboratory Quality Assurance Committee. (2015). Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine, 17(5), 405-424. https://doi.org/10.1038/gim.2015.30
Seale, P., Bjork, B., Yang, W., Kajimura, S., Chin, S., Kuang, S., … Spiegelman, B. M. (2008). PRDM16 controls a brown fat/skeletal muscle switch. Nature, 454(7207), 961-967. https://doi.org/10.1038/nature07182
Sedaghat-Hamedani, F., Haas, J., Zhu, F., Geier, C., Kayvanpour, E., Liss, M., … Meder, B. (2017). Clinical genetics and outcome of left ventricular non-compaction cardiomyopathy. European Heart Journal, 38(46), 3449-3460. https://doi.org/10.1093/eurheartj/ehx545
Thevenon, J., Duffourd, Y., Masurel-Paulet, A., Lefebvre, M., Feillet, F., El Chehadeh-Djebbar, S., … Rivière, J. B. (2016). Diagnostic odyssey in severe neurodevelopmental disorders: Toward clinical whole-exome sequencing as a first-line diagnostic test. Clinical Genetics, 89(6), 700-707. https://doi.org/10.1111/cge.12732
Towbin, J. A., Lorts, A., & Jefferies, J. L. (2015). Left ventricular non-compaction cardiomyopathy. Lancet (London, England), 386(9995), 813-825. https://doi.org/10.1016/S0140-6736(14)61282-4
van Waning, J. I., Caliskan, K., Hoedemaekers, Y. M., van Spaendonck-Zwarts, K. Y., Baas, A. F., Boekholdt, S. M., … Majoor-Krakauer, D. (2018). Genetics, clinical features, and long-term outcome of noncompaction cardiomyopathy. Journal of the American College of Cardiology, 71(7), 711-722. https://doi.org/10.1016/j.jacc.2017.12.019
Ware, J. S., & Cook, S. A. (2018). Role of titin in cardiomyopathy: From DNA variants to patient stratification. Nature Reviews Cardiology, 15(4), 241-252. https://doi.org/10.1038/nrcardio.2017.190
Zaveri, H. P., Beck, T. F., Hernández-García, A., Shelly, K. E., Montgomery, T., van Haeringen, A., … Scott, D. A. (2014). Identification of critical regions and candidate genes for cardiovascular malformations and cardiomyopathy associated with deletions of chromosome 1p36. PLoS One, 9(1), e85600. https://doi.org/10.1371/journal.pone.0085600

Auteurs

Geoffroy Delplancq (G)

Laboratoire de Génétique chromosomique et moléculaire, UF Innovation en diagnostic génomique des maladies rares, Centre Hospitalier Universitaire de Dijon, Dijon, France.

Georges Tarris (G)

Département d'Anatomopathologie, Dijon, France.

Antonio Vitobello (A)

Laboratoire de Génétique chromosomique et moléculaire, UF Innovation en diagnostic génomique des maladies rares, Centre Hospitalier Universitaire de Dijon, Dijon, France.
Équipe GAD (Génétique des Anomalies du Développement), UMR INSERM 1231, Université de Bourgogne, Dijon, France.

Sophie Nambot (S)

Équipe GAD (Génétique des Anomalies du Développement), UMR INSERM 1231, Université de Bourgogne, Dijon, France.
Centre de Génétique et Centre de Référence Maladies Rares 'Anomalies du Développement' de l'Interrégion Est, Hôpital d'Enfants, CHU, Dijon, France.

Arthur Sorlin (A)

Laboratoire de Génétique chromosomique et moléculaire, UF Innovation en diagnostic génomique des maladies rares, Centre Hospitalier Universitaire de Dijon, Dijon, France.
Équipe GAD (Génétique des Anomalies du Développement), UMR INSERM 1231, Université de Bourgogne, Dijon, France.

Christophe Philippe (C)

Laboratoire de Génétique chromosomique et moléculaire, UF Innovation en diagnostic génomique des maladies rares, Centre Hospitalier Universitaire de Dijon, Dijon, France.
Équipe GAD (Génétique des Anomalies du Développement), UMR INSERM 1231, Université de Bourgogne, Dijon, France.
Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), Centre Hospitalier Universitaire de Dijon et Université de Bourgogne-Franche Comté, Dijon, France.

Virginie Carmignac (V)

Équipe GAD (Génétique des Anomalies du Développement), UMR INSERM 1231, Université de Bourgogne, Dijon, France.
Centre de référence MAGEC (Maladies génétiques à expression cutanée), CHU Dijon, Dijon, France.

Yannis Duffourd (Y)

Équipe GAD (Génétique des Anomalies du Développement), UMR INSERM 1231, Université de Bourgogne, Dijon, France.
Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), Centre Hospitalier Universitaire de Dijon et Université de Bourgogne-Franche Comté, Dijon, France.

Charlotte Denis (C)

Département de Cardiologie Pédiatrique, CHU Dijon, Dijon, France.

Jean Christophe Eicher (JC)

Département de Cardiologie, CHU Dijon, Dijon, France.

Martin Chevarin (M)

Laboratoire de Génétique chromosomique et moléculaire, UF Innovation en diagnostic génomique des maladies rares, Centre Hospitalier Universitaire de Dijon, Dijon, France.
Équipe GAD (Génétique des Anomalies du Développement), UMR INSERM 1231, Université de Bourgogne, Dijon, France.

Gilles Millat (G)

Laboratoire Cardiogénétique, Centre de Biologie et Pathologie Est, CHU de Lyon HCL - GH Est, Lyon, France.

Bouchra Khallouk (B)

Département de Gynécologie Obstétrique, CHU Dijon, Dijon, France.

Thierry Rousseau (T)

Département de Gynécologie Obstétrique, CHU Dijon, Dijon, France.

Sylvie Falcon-Eicher (S)

Département de Cardiologie Pédiatrique, CHU Dijon, Dijon, France.

Alexandre Vasiljevic (A)

Institut de Pathologie Multi-sites des HCL/Centre de Pathologie et Fœtopathologie Est, CHU Lyon, Lyon, France.

Fara T Harizay (FT)

Département d'Anatomopathologie, Dijon, France.

Christel Thauvin-Robinet (C)

Laboratoire de Génétique chromosomique et moléculaire, UF Innovation en diagnostic génomique des maladies rares, Centre Hospitalier Universitaire de Dijon, Dijon, France.
Équipe GAD (Génétique des Anomalies du Développement), UMR INSERM 1231, Université de Bourgogne, Dijon, France.
Centre de Génétique et Centre de Référence Maladies Rares 'Anomalies du Développement' de l'Interrégion Est, Hôpital d'Enfants, CHU, Dijon, France.
Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), Centre Hospitalier Universitaire de Dijon et Université de Bourgogne-Franche Comté, Dijon, France.

Laurence Faivre (L)

Équipe GAD (Génétique des Anomalies du Développement), UMR INSERM 1231, Université de Bourgogne, Dijon, France.
Centre de Génétique et Centre de Référence Maladies Rares 'Anomalies du Développement' de l'Interrégion Est, Hôpital d'Enfants, CHU, Dijon, France.
Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), Centre Hospitalier Universitaire de Dijon et Université de Bourgogne-Franche Comté, Dijon, France.

Paul Kuentz (P)

Équipe GAD (Génétique des Anomalies du Développement), UMR INSERM 1231, Université de Bourgogne, Dijon, France.
Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), Centre Hospitalier Universitaire de Dijon et Université de Bourgogne-Franche Comté, Dijon, France.
Génétique biologique, PCBio, Centre Hospitalier Universitaire de Besançon, Besançon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH